Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst (NASDAQ:HCAT) and maintained a price target of $16.
August 20, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Sarah James has reiterated an Overweight rating for Health Catalyst, maintaining a $16 price target. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $16 price target by a reputable analyst suggests a positive outlook for Health Catalyst. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100